WO2008007021A1 - Methode d'immunisation contre les 4 serotypes de la dengue - Google Patents
Methode d'immunisation contre les 4 serotypes de la dengue Download PDFInfo
- Publication number
- WO2008007021A1 WO2008007021A1 PCT/FR2007/051641 FR2007051641W WO2008007021A1 WO 2008007021 A1 WO2008007021 A1 WO 2008007021A1 FR 2007051641 W FR2007051641 W FR 2007051641W WO 2008007021 A1 WO2008007021 A1 WO 2008007021A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dengue
- vaccine
- serotype
- den
- virus
- Prior art date
Links
- 206010012310 Dengue fever Diseases 0.000 title claims abstract description 164
- 208000025729 dengue disease Diseases 0.000 title claims abstract description 158
- 208000001490 Dengue Diseases 0.000 title claims abstract description 155
- 238000000034 method Methods 0.000 title abstract description 19
- 238000002649 immunization Methods 0.000 title description 44
- 241000700605 Viruses Species 0.000 claims abstract description 152
- 229960005486 vaccine Drugs 0.000 claims description 166
- 239000000203 mixture Substances 0.000 claims description 58
- 229940031416 bivalent vaccine Drugs 0.000 claims description 9
- 101000708009 Homo sapiens Sentrin-specific protease 8 Proteins 0.000 claims description 7
- 102100031407 Sentrin-specific protease 8 Human genes 0.000 claims description 7
- 229940001442 combination vaccine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 230000003053 immunization Effects 0.000 description 44
- 208000015181 infectious disease Diseases 0.000 description 22
- 241000615954 Varroa destructor virus-1 Species 0.000 description 20
- 208000003152 Yellow Fever Diseases 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 17
- 241000282693 Cercopithecidae Species 0.000 description 16
- 206010058874 Viraemia Diseases 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 241000725619 Dengue virus Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000002238 attenuated effect Effects 0.000 description 11
- 101100112679 Caenorhabditis elegans cyd-1 gene Proteins 0.000 description 10
- 101100169267 Escherichia coli (strain K12) cydA gene Proteins 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 9
- 101100169272 Escherichia coli (strain K12) cydB gene Proteins 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 241000710829 Dengue virus group Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000256118 Aedes aegypti Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000282596 Hylobatidae Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101100450407 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM1 gene Proteins 0.000 description 1
- 208000009714 Severe Dengue Diseases 0.000 description 1
- 244000025012 Spondias pinnata Species 0.000 description 1
- 235000005658 Spondias pinnata Nutrition 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000028857 Tropical infectious disease Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229940124928 YF-Vax Drugs 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003441 anti-flavivirus Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the subject of the invention is a method for inducing homologous protection against the four serotypes of dengue in a patient, comprising sequentially administering to said patient (i) a dose of a dengue vaccine virus. a first serotype and a dose of a vaccine virus dengue a second serotype, and (ii) a dose of a vaccine virus dengue a third serotype and a dose of a dengue vaccine virus of a fourth serotype, in which the dengue vaccine viruses (ii) are administered at least 30 days and at most 1 year after administration of the dengue vaccine viruses (i).
- Dengue diseases are caused by four closely related, but antigenically distinct, flavivirus-like viruses of the serotype type (G ⁇ bler et al., 1988 In: Epidemiology of arthropod-terminal viral disease.) Monath TPM, editor, Boca Raton (FL) ): CRC Press: 223-60, Kautner et al., 1997, J. of Pediatrics, 131: 516-524, Rigau-Pérez et al., 1998, Lancet, 352: 971 -977, Vaughn et al., 1997 J Infect Dis; 176: 322-30). Infection with a dengue serotype can produce a spectrum of clinical illness ranging from nonspecific viral syndrome to fatal severe haemorrhagic disease.
- the incubation period of dengue fever after mosquito bite is about 4 days (ranging from 3 to 14 days).
- Dengue fever is characterized by biphasic fever, headache, pain in various parts of the body, prostration, rash, lymphadenopathy and leukopenia (Kautner et al., 1997, J. of Pediatrics, 131: 516 Rigau-Pérez et al., 1998, Lancet, 352: 971-977).
- the viremic period is the same as for febrile diseases (Vaughn et al., 1997, J. Infect Dis, 176: 322-30).
- the cure of dengue fever is acquired after 7 to 10 days, but prolonged asthenia is usual. Decreases in leukocyte and platelet count are common.
- Dengue haemorrhagic fever is a severe febrile illness characterized by abnormalities of homeostasis and an increase in vascular permeability that can lead to hypovolemia and hypotension (dengue with shock syndrome) often complicated by internal bleeding. severe.
- the mortality rate of dengue haemorrhagic fever can reach up to 10% without therapy, but is 1% in most centers with therapeutic experience (WHO technical guide, 1986. Dengue haemorrhagic fever: diagnosis, treatment and control, p1 -2 World Health Organization, Geneva, Switzerland).
- Routine laboratory diagnosis of dengue fever is based on virus isolation and / or detection of dengue virus specific antibodies.
- Dengue is the second most important tropical infectious disease after malaria, with more than half of the world's population (2.5 billion) living in areas at risk of epidemic transmission. Each year, dengue cases are estimated at 50-100 million, cases of patients hospitalized for dengue haemorrhagic at 500 000, and the number of deaths at 25 000. Dengue is endemic in Asia, the Pacific, Africa , in Latin America and the Caribbean. More than 100 tropical countries are endemic for dengue virus and dengue haemorrhagic infections have been documented in 60 of these countries (Gubler, 2002, TRENDS in Microbiology, 10: 100-103, Monath, 1994, Proc Natl Acad Sci 91: 2395-2400).
- dengue fever A number of well-described factors appear to be involved in dengue fever: population growth; unplanned and uncontrolled urbanization, especially in association with poverty; an increase in air travel; lack of effective mosquito control and deterioration of health and public health infrastructure (Gubler, 2002, TRENDS in Microbiology, 10: 100-103). Travelers and expatriates are increasingly alerted to dengue fever (Shirtcliffe et al., 1998, J. Roy, Phys Phys., London, 32: 235-237). Dengue fever has been a leading cause of febrile illness in US troops during deployments in tropical areas endemic for dengue fever (DeFraites et al., 1994, MMWR 1994; 43: 845-848). The viruses are kept in a cycle that involves humans and
- Aedes aegypti a domestic mosquito piquing the day, who prefers to feed on humans. Infection in humans is initiated by injecting the virus during the blood meal of an infected Aedes aegypti mosquito.
- the virus Salivary is deposited mainly in extravascular tissues.
- the first class of infected cells after inoculation are the dendritic cells, which then migrate to the lymph nodes (Wu et al., 2000, Nature Med., 7: 816-820). After initial replication in the skin and in the lymph nodes, the virus appears in the blood during the acute febrile phase, usually for 3-5 days.
- Monocytes and macrophages are, along with dendritic cells, among the first targets of the dengue virus. Protection against homotypic reinfection is complete and probably lasts a lifetime, but cross-protection between different types of dengue lasts less than a few weeks to a few months (Sabin, 1952, Am. J. Trop., Med Hyg .; : 30-50). As a result, a subject may be infected with a different serotype. A second dengue infection is theoretically a risk factor for developing severe dengue fever. However, dengue haemorrhagic fever is multifactorial: these factors include the strain of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.
- dengue haemorrhagic fever Two factors play a major role in the occurrence of dengue haemorrhagic fever: rapid viral replication with high viremia (the severity of the disease being associated with the level of viremia, Vaughn et al., 2000, J. Dis. 181: 2-9) and a significant inflammatory response with the release of elevated levels of inflammatory mediators (Rothman and Ennis, 1999, Virology, 257: 1-6).
- the treatment of dengue fever is symptomatic with bed rest, fever and pain control with antipyretics and analgesics, and adequate drinking.
- Treatment of dengue haemorrhagic fever requires the balancing of fluid loss, replacement of clotting factors and heparin infusion.
- Price (1968, Am. J. Epid., 88: 392-397) described a method of sequential immunization against dengue including a series of two infections with dengue serotype 1 and then with dengue serotype 2 which conferred a protection in a challenge test with dengue serotype 3 or 4.
- the objective is to induce homologous protection against the four serotypes of dengue fever.
- the inventors have demonstrated that it is possible to generate an immune response comprising antibodies neutralizing the four serotypes when they are administered sequentially two by two.
- the inventors have in particular shown that a bivalent immunization
- DEN-1, 2 followed two months later by a bivalent immunization DEN-3,4 induces high responses against all four serotypes in all immunized monkeys.
- the immune response thus generated is more important quantitatively and qualitatively (covers all serotypes).
- the present invention thus relates to vaccine compositions comprising (i) a dose of a vaccine virus of dengue of a first serotype and a dose of a vaccine virus of dengue of a second serotype, and ii) one dose of a third serotype dengue vaccine virus and one dose of a fourth serotype dengue vaccine virus, as a combination dengue combination vaccine composition for sequential administration, wherein vaccine viruses from dengue fever
- the vaccine viruses (ii) are administered 30 days to 3 months after administration of the vaccine viruses (i)
- the vaccine viruses (ii) are administered 30 days after administration of the vaccine viruses (i).
- the dengue vaccine viruses (i) are administered in the form of a bivalent vaccine composition.
- the dengue vaccine viruses (ii) are administered in the form of a bivalent vaccine composition.
- said serotype 1 dengue vaccine virus is selected from the group consisting of the VDV1 strain and a ChimeriVax TM DEN-1.
- said vaccinal dengue serotype 2 virus is selected from the group consisting of the VDV2 strain and a ChimeriVax TM DEN-2.
- said serotype 1 dengue vaccine virus is the VDV1 strain and said serotype 2 dengue vaccine virus is the VDV2 strain.
- said serotype 1 dengue vaccine virus is a ChimeriVax TM DEN-1 and said serotype 2 dengue vaccine virus is a ChimeriVax TM DEN-2.
- said vaccine virus of dengue serotype 3 is a ChimeriVax TM DEN-3.
- said serotype 4 dengue vaccine virus is a ChimeriVax TM DEN-4.
- the first and second serotypes are respectively CYD DEN1 and CYD DEN2 and the third and fourth serotypes are respectively CYD DEN 3 and CYD DEN 4.
- the vaccine virus doses of dengue fever Serotypes 1, 2, 3 and 4 are each in a range of from 10 3 to 10 5 CCID 50 .
- the invention also relates to the use of a dengue vaccine virus of a third serotype and a dengue vaccine virus of a fourth serotype for the manufacture of a dengue vaccine intended to be administered to a patient who received, at least 30 days and not more than 1 year previously, a dose of a dengue vaccine virus of a first serotype and a dose of a vaccine virus of dengue of a second serotype.
- the third and fourth serotypes are administered in the form of a bivalent vaccine composition.
- the first and second serotypes are administered in the form of a bivalent vaccine composition.
- said serotype 1 dengue vaccine virus is selected from the group consisting of the VDV1 strain and a ChimeriVax TM DEN-1.
- said serotype 2 dengue vaccine virus is selected from the group consisting of the VDV2 strain and a ChimeriVax TM DEN-2.
- said serotype 1 dengue vaccine virus is the VDV1 strain and said serotype 2 dengue vaccine virus is the VDV2 strain.
- said serotype 1 dengue vaccine virus is a ChimeriVax TM DEN-1 and said serotype 2 dengue vaccine virus is a ChimeriVax TM DEN-2.
- said vaccine virus of dengue serotype 3 is a ChimeriVax TM DEN-3.
- said serotype 4 dengue vaccine virus is a ChimeriVax TM DEN-4.
- the first and second serotypes are respectively CYD DEN1 and CYD DEN2 and the third and fourth serotypes are respectively CYD DEN 3 and CYD DEN 4.
- the third and fourth serotypes are administered 30 days to 3 months after the administration of the first and second serotypes.
- the third and fourth serotypes are administered 30 days after the administration of the first and second serotypes.
- the vaccine virus doses of dengue serotype 1, 2, 3 and 4 are each in a range from 10 3 to 10 5 DICC 50 .
- DEN Single-stranded, positive-strand RNA viruses belonging to the genus Flavivirus of the flaviviridae family.
- the genomic RNA contains a type I cap at the 5 'end but lacks a poly-A tail at the 3' end.
- the genomic organization consists of the following: 5 'non-coding region (NCR), structural proteins (capsid (C), pre-membrane / membrane (prM / M), envelope (E)) and non-structural proteins (NS1 - NS2A-NS2B-NS3-NS4A-NS4B-NS5) and NCR 3 '.
- the genomic viral RNA is associated with the capsid proteins to form a nucleocapsid.
- the DEN viral genome encodes an uninterrupted coding region that is translated into a single polyprotein.
- VDV or “Vero Dengue Vaccine” refers to a live attenuated viral dengue strain adapted to Vero cells and capable of inducing a response humoral specificity, including the induction of neutralizing antibodies, in primates and in particular in humans.
- VDV-1 is a strain obtained from a DEN-1 16007 wild-type strain which had undergone 11 passages on PDK cells (DEN-1 16007 / PDK1 1) which was then amplified on Vero cells at 32 ° C, and whose RNA has been purified and transfected into Vero cells.
- the strain VDV-1 has 14 additional mutations compared to the vaccine strain DEN-1 16007 / PDK13 (13 passages on PDK -Primary Dog Kidney cells).
- the strain DEN-1 16007 / PDK13 also called “LAV1”
- LAV1 has been described in the patent application EP1 159968 in the name of Mahidol University and has been deposited with the National Collection of Cultures of Microorganisms (CNCM) under the number I -2480.
- the complete sequence of the VDV-1 strain is given to the sequence SEQ ID NO: 1. Said strain can be easily reproduced from said sequence.
- a method of preparation and the characterization of the strain VDV-1 have been described in the international patent application filed in the names of Sanofi Pasteur and the Center for Disease Control and Prevention under the number PCT / IB 2006/001313.
- VDV-2 is a strain obtained from a wild-type strain DEN-2 16681 which has undergone 50 passages on PDK cells (DEN-2 16681 / PDK50), purified by plate and whose RNA has been extracted and purified before to be transfected into Vero cells. The VDV-2 strain was then obtained by plaque purification and amplification on Vero cells. The strain VDV-2 has 10 additional mutations compared to the DEN-2 16681 / PDK53 vaccine strain (53 passages on PDK cells), including 4 silent mutations.
- the strain DEN-2 16681 / PDK53 also called “LAV2”
- LAV2 has been described in patent application EP1 159968 in the name of Mahidol University and has been filed with the National Collection of Cultures of Microorganisms (CNCM) under the number 1 -2481.
- the complete sequence of the VDV-2 strain is shown in the sequence SEQ ID NO: 2.
- the VDV-2 strain can be easily reproduced from said sequence.
- a method of preparation and characterization of the VDV-2 strain has been described in the international patent application filed in the names of Sanofi Pasteur and the Center for Disease Control and Prevention under the number PCT / IB 2006/001513.
- CYD ChimeriVax TM Dengue
- CYD refers to a chimeric yellow fever (YF) virus that comprises the backbone of a YF virus in which the coding sequences for the pre-membrane and envelope proteins have been replaced. by those of a DEN virus.
- CYD-1 or CYD DEN1 is a chimeric YF virus containing the prM and E sequences of a dengue serotype 1 (DEN-I) strain.
- CYD-2 or CYD DEN2 refers to a chimeric YF virus containing the prM and E sequences of a DEN-2 strain.
- CYD-3 or CYD DEN3 is a chimeric YF virus containing the prM and E sequences of a DEN-3 strain.
- CYD-4 or CYD DEN4 refers to a chimeric YF virus containing the prM and E sequences of a DEN-4 strain.
- the preparation of these dengue ChimeriVax TM has been described in detail in international patent applications WO 98/3791 1 and WO 03/101397 to which reference can be made for a precise description of their preparation process.
- chimeras described in the examples were generated using the prM and E sequences derived from the DEN 1 PUO359, DEN2 PR159, DEN3 PaH881 and DEN4 TVP980 strains. Any strain of the dengue virus could be used as part of the present invention for the construction of chimeras.
- the chimeric YF virus comprises the backbone of an attenuated yellow fever strain YF17D (Theiler M, and Smith HH (1937) J Exp. Med 65, p767-786.) (YF17D / DEN-1 virus, YF17D / DEN-2, YF17D / DEN-3, YF17D / DEN-4).
- YF17D strains that may be used include YF17D204 (YF-Vax®, Sanofi Pasteur, Swifwater, PA, USA, Stamaril®, Sanofi Pasteur, Marcy Star, France, ARILVAX TM, Chiron, Speke, Liverpool, UK).
- a “monovalent” vaccine contains a single serotype of dengue virus.
- a “bivalent” vaccine contains two different serotypes of dengue virus.
- a “trivalent” vaccine contains three different serotypes of dengue virus.
- a “tetravalent” vaccine contains four different dengue virus serotypes.
- Patient refers to a person (child or adult) who may be infected with dengue fever, particularly a person at risk of infection, such as a person traveling to areas where dengue fever is present or an inhabitant of dengue fever. these regions.
- the inventors therefore propose a method for inducing a neutralizing antibody response against the four dengue serotypes in a patient, comprising sequentially administering to said patient (i) a dose of a dengue vaccine virus of a first serotype. and a dose of a dengue vaccine virus of a second serotype, and (ii) a dose of a dengue vaccine virus of a third serotype and a dose of a vaccine virus dengue fever of a fourth serotype, in which the dengue vaccine viruses (ii) are administered at least 30 days and at most 3 months after administration of the dengue vaccine viruses (i).
- dengue vaccine virus in the context of the present invention, any viral form of the dengue virus which is capable of inducing a specific hommologue response.
- the dengue vaccine virus can be used as part of an immunization program in humans against dengue virus infection.
- dengue vaccine virus is therefore meant an inactivated virus, an attenuated virus as well as recombinant proteins such as dengue virus envelope protein.
- a vaccine virus is "inactivated” if it can no longer replicate on permissive cells.
- a vaccine virus is "attenuated” if after growth at 37 ° C or 39 ° C on Huh-7, VERO and / or C6 / C36 cells, such a virus has a titre that is at least 10 times lower than the maximum titre of wild type, as determined under the same culture conditions and using the same method of titration.
- a vaccine virus exhibiting decreased growth on at least one of these three cell types identified above is considered to be attenuated within the scope of the present invention.
- a vaccine virus that can be used in humans has a positive risk / benefit ratio that meets the regulatory requirements for placing on the market.
- a dengue vaccine virus used in the context of the present invention is preferably attenuated so that it does not induce disease in humans.
- such a vaccine virus leads only to side effects which are at most of moderate intensity (i.e. average to low or even zero) in the majority of vaccinated subjects, while maintaining its ability to induce a homologous response comprising neutralizing antibodies.
- Non-limiting examples of vaccinal dengue viruses that may be used in the context of the present invention include inactivated dengue viruses, attenuated dengue viruses, such as attenuated VDV-1 strains, VDV-2, the strains described for example in the applications WO02 / 66621, WO00 / 57904, WO00 / 57908, WO00 / 507909, WO00 / 57910, WO02 / 0950075 and the chimeras.
- the chimeric viruses have the characteristics of the attenuated viruses as defined above.
- Any chimeric virus expressing an envelope protein of a dengue virus and inducing an immune response comprising antibodies neutralizing the serotype from which the protein is derived can be used within the scope of the present invention.
- Nonlimiting examples include ChimeriVaxTM dengue as described for example in WO98 / 3791 1, as well as dengue / dengue chimeras as described for example in patent applications WO96 / 40933 and WO01 / 60847.
- the vaccinal dengue serotype 1 virus may be, for example, the vaccine strain VDV1 or a ChimeriVax TM DEN-1, in particular a YF17D / DEN-1 virus, or a DEN-1 16007 / PDK13 strain.
- the vaccine virus of dengue serotype 2 can be for example the vaccine strain VDV2 or a ChimeriVax TM DEN-2, in particular a YF17D / DEN-2 virus, or a DEN-2 16681 / PDK53 strain.
- the vaccine virus of serotype 3 dengue fever may be a ChimeriVax TM DEN-3, particularly a YF17D / DEN-3 virus.
- the vaccine virus of dengue serotype 4 may be a ChimeriVax TM DEN-4, in particular a YF17D / DEN-4 virus. It may also be a strain "LAV4" or "DEN-4 1036 / PDK48" that is to say a strain DEN-4 1036 attenuated by 48 passages on PDK cells. This strain has been described in patent application EP1 159968 in the name of Mahidol University and has been filed with the National Collection of Cultures of Microorganisms (CNCM) under the number 1-2483.
- CNCM National Collection of Cultures of Microorganisms
- Each ChimeriVax TM monovalent dengue vaccine virus (serotypes 1, 2, 3 and 4) was prepared by amplification of each serotype on Vero cells. More specifically, the four viruses are produced separately on adherent Vero cells in serum-free medium. The viral harvest, clarified from cell debris by filtration, is then concentrated and purified by ultrafiltration and chromatography to remove DNA from the host cells. After addition of a stabilizer, the vaccine strains are stored frozen or lyophilized before use and then reconstituted extemporaneously. The same process is applied for the four chimeras. Strains VDV 1 and 2 are prepared by amplification on cells
- Vero Viruses produced are harvested and clarified from cellular debris by filtration.
- the DNA is digested by enzymatic treatment.
- the impurities are removed by ultrafiltration.
- Infectious titres may be increased by a concentration method.
- the strains are stored in freeze-dried or frozen form before use and then reconstituted extemporaneously.
- the multivalent compositions are obtained by simple mixing of the monovalent compositions.
- the four serotypes of dengue fever can be administered in any order provided they are administered two by two sequentially within a period of 30 days to 1 year, such as 30 days, 45 days, 60 days, 3 months, 6 months, 9 months and 1 years, advantageously a period of 30 days to 3 months, in particular a period of 1 to 2 months, between the two series of administration.
- the method according to the present invention can therefore be implemented with the embodiments described below: - (i): serotypes 1 and 2; (ii) serotypes 3 and 4; or
- the present invention therefore covers the following diagrams:
- VDV-1 and CYD DEN-4 (i) VDV-1 and CYD DEN-4; (ii) CYD DEN-2 and CYD DEN-3 - (i) CYD DEN-2 and CYD DEN-3; (ii) VDV-1 and CYD DEN-4 - (i) CYD DEN-2 and CYD DEN-4; (ii) VDV-1 and CYD DEN-3 - (i) CYD DEN-3 and CYD DEN-4; (ii) VDV-1 and CYD DEN-2 - (i) CYD DEN-1 and VDV-2; (ii) CYD DEN-3 and CYD DEN-4
- VDV-1 and VDV-2 (i) CYD DEN-3 and CYD DEN-4 - (i) VDV-1 and CYD DEN-3; (ii) VDV-2 and CYD DEN-4 - (i) VDV-1 and CYD DEN-4; (ii) VDV-2 and CYD DEN-3 - (i) VDV-2 and CYD DEN-3; (ii) VDV-1 and CYD DEN-4 - (i) VDV-2 and CYD DEN-4; (ii) VDV-1 and CYD DEN-3 and - (i) CYD DEN-3 and CYD DEN-4; (ii) VDV-1 and VDV-2 and VDV-2 and CYD DEN-4; (ii) VDV-1 and CYD DEN-3 and - (i) CYD DEN-3 and CYD DEN-4; (ii) VDV-1 and VDV-2 and VDV-2; (ii) VDV-1 and CYD DEN-3 and - (
- the term "vaccine virus dose” is intended to mean a composition comprising an "immunoefficient amount" of the vaccinia virus, that is to say a sufficient quantity of virus to induce a homologous neutralizing antibody response, which can be demonstrated for example by the seroneutralization test as described below in Examplei.
- a serum is considered positive for the presence of neutralizing antibodies when the neutralizing antibody titer thus determined is greater than or equal to 1: 10.
- Vaccine strain amounts are commonly expressed in terms of plaque forming unit (PFU) or infective dose 50% of tissue culture (TCID 50 ), or of infective dose 50% of cell culture (DICC50).
- PFU plaque forming unit
- TCID 50 tissue culture
- DICC50 infective dose 50% of cell culture
- the compositions according to the invention may contain from 10 to 10 6 DICC 50 , in particular from 10 3 to 10 5 DICC 50 dengue vaccine virus of serotype 1, 2, 3 or 4 for a monovalent or bivalent composition.
- the vaccine virus doses of dengue serotype 1, 2, 3 and 4 are preferably each in a range from 10 to 10 6 DICC 50 , such as 10, 10 1 , 2 2 , 3 , 10 4 , 10 5 or 10 6 DICC 50, in particular in a range from 10 3 to 10 5 DICC 50 .
- the vaccine viruses can be used in identical or different doses, which can be adjusted in depending on the nature of the vaccine virus used and the intensity of the immune response obtained.
- the homologous neutralizing antibody response is durable, i.e., it can be detected in the serum at least 6 months after the administration of the dengue serotypes (ii)
- the third and fourth serovar dengue vaccine viruses are administered at least 30 days and at most 12 months after administration of the first and second serovar dengue vaccine viruses.
- the dengue vaccine viruses of the third and fourth serotypes may for example be administered 30 days to 1 year, for example 30 days, 45 days, 60 days, 3 months, 6 months, 9 months or 1 year, advantageously 30 days to 3 months, in particular 1 to 2 months, after administration of the dengue vaccine viruses of the first and second serotypes.
- the dose of a vaccine virus of the dengue of a first serotype and the dose of a vaccine virus of the dengue of a second serotype are administered simultaneously in the form of two monovalent compositions, or in the form of a single composition bivalent.
- the dose of a third serotype dengue vaccine virus and the dose of a fourth serotype dengue vaccine virus are administered simultaneously.
- the third and fourth serotypes can be administered simultaneously as two monovalent vaccine compositions, or as a single, bivalent vaccine composition.
- the vaccine viruses are administered in the form of vaccine compositions which can be prepared according to any method known to those skilled in the art.
- viruses generally in freeze-dried form, are mixed with a pharmaceutically acceptable excipient, such as water or phosphate buffered saline, wetting or stabilizing agents.
- pharmaceutically acceptable excipient is meant any solvent, dispersion medium, charge etc, which does not produce a side reaction, for example allergic, in humans or animals.
- the excipient is selected according to the chosen dosage form, method and route of administration. Suitable excipients, as well as pharmaceutical formulation requirements, are described in "Remington: The Science & Practice of Pharmacy", which is a reference work in the field.
- the vaccine compositions are prepared in injectable form, and may correspond to liquid solutions, suspensions or emulsions.
- the compositions may in particular comprise a aqueous solution buffered to maintain a pH of between about 6 and 9 (as determined with a pH meter at room temperature).
- compositions may nevertheless comprise such a compound, that is to say a substance that increases, stimulates or strengthens the cellular or humoral immune response induced by the vaccine strain. administered simultaneously.
- a compound that is to say a substance that increases, stimulates or strengthens the cellular or humoral immune response induced by the vaccine strain. administered simultaneously.
- the vaccine compositions according to the invention may be administered according to any route usually used for vaccination, for example the parenteral route (especially intradermal, subcutaneous, or intramuscular).
- the vaccine compositions are injectable compositions administered subcutaneously in the deltoid region.
- the volume of composition administered depends on the route of administration. For subcutaneous injections, the volume is generally between 0.1 and 1.0 ml, preferably about 0.5 ml.
- the optimal period for administering the first and second serotypes, or preferably all serotypes 1 to 4 is approximately 1 to 3 months before exposure to the dengue virus.
- the vaccines can be administered as a prophylactic treatment for dengue virus infection in adults and children.
- Target populations therefore include individuals who may be naive (ie, not previously immunized) or non-naive with respect to the dengue virus.
- Dengue vaccine serovar vaccine administrations of serotypes 1 to 4 can also be implemented for example between 6 months and 10 years, for example 6 months, 1 year, 3 years, 5 years or 10 years after the administration. third and fourth serotypes.
- the present invention also provides an immunization kit comprising 4 dengue vaccine viruses of 4 different serotypes in which each serotype is present in the form of a vaccine dose, or wherein at least 2 or even 4 serotypes are present as a bivalent composition.
- Viremia and immunogenicity were therefore tested in a monkey model.
- Viremia in particular, has been identified as one of the factors associated with virulence and severity of illness in men and is therefore an important parameter to consider. Immunogenicity is a key parameter in the assessment of protection conferred.
- the monkeys were immunized subcutaneously in the arm (s) with 0.5 ml of vaccine composition. After mild anesthesia with ketamine (Imalgene, Merial), blood was collected by puncture at the inguinal or saphenous veins. At days 0 and 28, 5 ml of blood was sampled to evaluate antibody responses, while between days 2 and 10, 1 ml of blood was sampled to assess viremia. Blood was collected on ice and kept on ice until serum was separated. For this, the blood was centrifuged for 20 minutes at 4 ° C and the collected serum stored at -80 ° C until testing.
- ketamine Intra, Merial
- RNAs Seven plasmids containing, under the control of the T7 promoter, the region targeted by each PCR, were transcribed in vitro to generate a series of synthetic RNAs that were included as internal reference in each RT-PCT assay. These synthetic RNAs were assayed by spectrophotometry, the amount of RNA obtained was converted into RNA copy number and expressed in GEQ (genomic equivalents).
- RNA 0.140 ml of monkey serum was extracted using Macherey Nagel's "Nucleospin 96 virus TM" RNA extraction kit, according to the manufacturer's instructions, and the purified RNA was eluted with 0.140 ml (0.090 ml). ml, then 0.05 ml) of RNase free water. To avoid repeated freeze / thaw cycles, a first quantification was performed immediately after the extraction of 5 ⁇ l of said RNA preparation. The remaining volume was frozen at 70 ° C.
- the reaction mixtures contained, in addition to the components of the Qiagen Qauntitect TM probes RT-PCR kit (Qiagen), 10 picomoles of each primer, 4 picomoles of each probe and 5 ⁇ l of RNA, in a total volume of 25. .mu.l.
- Qiagen Qauntitect TM probes RT-PCR kit
- 10 picomoles of each primer 4 picomoles of each probe and 5 ⁇ l of RNA, in a total volume of 25. .mu.l.
- 5 .mu.l of the purified preparation was directly introduced into the reaction mixture, without a prior dilution step.
- Synthetic RNAs were diluted 1:10 in RNAse-free water, and 7 dilutions containing approximately 10 to 10 6 GEQ in 5 ⁇ l were quantified in parallel to generate the standard curve.
- Quantification reactions were performed by the Applied Biosystem ABIPrism 700 TM instrument, using the following program: 50 ° C / 30 min, 95 ° C / 15 min, followed by 40 cycles of 95 ° C / 15 sec. 60 ° C / 60 sec.
- the limit of quantification of the viral RNA in this test is 2.9 to 3.3 logioGEQ / ml (800 to 2000 GEQ / ml, 4 to 10 GEQ / reaction), according to the PCR targets (standard deviation: + / -0.3 log-m)
- the correlation between the infectious titer and the quantification of viral RNA was established in parallel with the assays by analysis of 0.140 ml of negative monkey (OD) sera samples into which a known amount of infectious particles of the viruses served for immunization (CYD or VDV). Said control sera were prepared at two dilutions containing about 1 PFU and about 100 PFU in 5 ⁇ l (2.3 and 4.3 log 10 PFU / ml, respectively).
- YF-NS5 sense 5 1 GCACGGATGTAACAGACTGAAGA (23 bases)
- PRNT50 test 50% reduction in the number of PFUs. This test is heavy and material consuming, we developed the SN50 test, based on the reduction to 50% of the number of units measured in DICC50 test.
- a 96-well plate 0.120 ml of each decomplemented serum is added to 0.480 ml of diluent (ISCOVE 4% FCS) per well. Serial dilutions of a factor of 6 are carried out by transfer of 0.150 ml of serum into 0.450 ml of diluent. 450 ⁇ l of viral dilution at 2.7 log-m DICC50 / ml are added to each well to obtain 25 CCID50 / well. The plate is incubated at 37 ° C for 1 hour.
- 100 ⁇ l of each dilution are then distributed in 6 wells of a 96-well plate in which VERO cells were seeded 3 days before the start of the experiment at a density of 8000 cells / well, in 100 ⁇ l of ISCOVE medium. 4% SVF.
- the cells After 6 days of incubation at 37 ° C., in the presence of 5% of CO 2 , the cells are fixed with ethanol / acetone (70/30) at 4 ° C. for 15 minutes and then washed. 3 times in PBS and incubated for 1 h at 37 ° C. in the presence of 50 ⁇ l of a 1/2000 dilution of an anti-flavivirus monoclonal antibody (mAb 4G2).
- mAb 4G2 an anti-flavivirus monoclonal antibody
- the plates are then washed twice and incubated for 1 hour at 37 ° C. in the presence of 50 ⁇ l of a 1/1000 dilution of an anti-mouse IgG conjugated with alkaline phosphatase.
- the lysis ranges are revealed by adding 50 ⁇ l of a colored substrate: BCIP / NBT.
- Neutralizing antibody titers are calculated using the Karber formula as defined below:
- d represents the dilution leading to 100% neutralization (ie 6 negative replicates that is to say having no sign of infection)
- the viral detection limit is 10 SN50 (i.e 1.0 Iog- 0 SN50).
- Viral strains that have been used for the neutralization are the strains
- the average title is established by calculating the geometric mean of the titles expressed in linear value, the samples whose title is lower than the detection threshold are assigned, by convention, a value equal to half of this threshold.
- Immunization was performed subcutaneously in the arm with a 23G1 needle at a dose of 10 5 DICC 50 for each serotype for CYD DEN vaccines 1 to 4.
- VDV-1 and VDV-2 were injected a dose of 3.96 log-m and 4.84 log-m respectively.
- the administration scheme according to the present invention makes it possible to increase qualitatively and quantitatively the homologous neutralizing antibody response which is obtained with the tetravalent vaccination.
- - Viremia (Table 4) is predominantly CYD-4 caused by CYD vaccines and no difference is observed between two sequential bivalent administrations and tetravalent administration (Group 2 vs. Group 3). Thus, no difference in safety after two bivalent immunizations or tetravalent immunization is expected. There is even a tendency towards lower viremia with the vaccine regimen according to the invention, see for example group 2 with respect to group 3.
- Example 2 Sequential immunization in the monkey conducted at 1 month interval. Comparison of CYD-1, 2 followed by CYD-3,4 versus CYD-2,3 followed by CYD-1, 4
- Viremia and immunogenicity were tested in a monkey model as in the previous example. In this example, an interval of one month was used between the two immunizations versus two months in the previous example.
- Primary immunization with the two most immunogenic vaccine viruses in the monkey (CYD-2,3) is followed by administration with the two immunodominant vaccine viruses (CYD-1,4).
- Immunization was performed subcutaneously in the arm with a 23G1 needle at a dose of 5 DICC 5 O for each serotype for CYD DEN vaccine viruses 1 to 4 as previously.
- the administration scheme according to the present invention makes it possible to increase qualitatively and quantitatively the homologous neutralizing antibody response which is obtained with the tetravalent vaccination when the two immunizations are carried out at 1 month intervals.
- the booster effect on serotypes 1 and 2 is less marked when the second administration is made after one month than when it is made after 2 months as in Example 1
- Example 1 shows that immunization done sequentially with two bivalents is effective in inducing a response against all serotypes in all animals, even when the booster is carried out only 1 month after primary immunization.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0712878-9A BRPI0712878A2 (pt) | 2006-07-12 | 2007-07-11 | métodos de imunização contra os 4 sorotipos de dengue |
EP07823563A EP2043680A1 (fr) | 2006-07-12 | 2007-07-11 | Methode d'immunisation contre les 4 serotypes de la dengue |
JP2009518935A JP5295956B2 (ja) | 2006-07-12 | 2007-07-11 | 4種のデング熱血清型に対する免疫付与の方法 |
MX2009000369A MX2009000369A (es) | 2006-07-12 | 2007-07-11 | Metodo de inmunizacion contra los cuatro serotipos de dengue. |
CN2007800263768A CN101489585B (zh) | 2006-07-12 | 2007-07-11 | 针对登革病毒四种血清型的免疫接种方法 |
CA002656349A CA2656349A1 (fr) | 2006-07-12 | 2007-07-11 | Methode d'immunisation contre les 4 serotypes de la dengue |
AU2007274100A AU2007274100B2 (en) | 2006-07-12 | 2007-07-11 | Method of immunisation against the four serotypes of dengue |
IL196331A IL196331A0 (en) | 2006-07-12 | 2009-01-01 | Method of immunization against the four serotypes of dengue |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0606324 | 2006-07-12 | ||
FR0606324A FR2903605A1 (fr) | 2006-07-12 | 2006-07-12 | Methode d'immunisation contre les quatres serotypes de la dengue |
US82936106P | 2006-10-13 | 2006-10-13 | |
US60/829,361 | 2006-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008007021A1 true WO2008007021A1 (fr) | 2008-01-17 |
Family
ID=37866217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/051641 WO2008007021A1 (fr) | 2006-07-12 | 2007-07-11 | Methode d'immunisation contre les 4 serotypes de la dengue |
Country Status (16)
Country | Link |
---|---|
US (2) | US7718357B2 (fr) |
EP (1) | EP2043680A1 (fr) |
JP (1) | JP5295956B2 (fr) |
KR (1) | KR20090027759A (fr) |
CN (1) | CN101489585B (fr) |
AR (1) | AR061887A1 (fr) |
AU (1) | AU2007274100B2 (fr) |
BR (1) | BRPI0712878A2 (fr) |
CA (1) | CA2656349A1 (fr) |
FR (1) | FR2903605A1 (fr) |
IL (1) | IL196331A0 (fr) |
MX (1) | MX2009000369A (fr) |
MY (1) | MY169275A (fr) |
TW (1) | TWI400333B (fr) |
WO (1) | WO2008007021A1 (fr) |
ZA (1) | ZA200900155B (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2526965A1 (fr) * | 2006-10-04 | 2012-11-28 | Sanofi Pasteur | Méthode d'immunisation contre les 4 sérotypes de la Dengue |
EP2099483B1 (fr) * | 2006-12-01 | 2013-12-25 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
WO2014016360A1 (fr) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Compositions de vaccin |
WO2014016362A1 (fr) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Compositions de vaccin pour prévenir une infection provoquée par le virus de la dengue |
WO2014083194A1 (fr) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Procédés d'induction d'anticorps |
US8999675B2 (en) | 2009-08-31 | 2015-04-07 | Gen-Probe Incorporated | Dengue virus assay |
WO2019069130A1 (fr) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | Compositions pour vaccination de rappel contre la dengue |
EP3620174A1 (fr) | 2018-09-05 | 2020-03-11 | Takeda Vaccines, Inc. | Dose unitaire de vaccin contre le virus de la dengue et son administration |
WO2021034349A1 (fr) | 2019-08-16 | 2021-02-25 | Takeda Vaccines, Inc. | Méthode de prévention de la dengue et de l'hépatite a |
WO2021174059A1 (fr) | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Procédé d'élimination d'adn de cellule hôte à partir d'une préparation virale |
WO2023147337A2 (fr) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Production et fabrication de vaccin à flavivirus à grande échelle |
WO2023158989A1 (fr) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Processus d'agitation par lots de vaccin contre la dengue |
WO2023215383A1 (fr) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Détermination par ordinateur d'une infectivité de flavivirus |
WO2024108087A1 (fr) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | Procédé de détermination de la proportion d'un flavivirus vivant atténué ayant une séquence nucléotidique comprenant au moins un locus d'atténuation dans une formulation |
WO2024118740A1 (fr) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Production et fabrication de vaccin à flavivirus à grande échelle |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193477A1 (en) * | 2005-08-10 | 2008-08-14 | Acambis Inc. | Vaccination Against Dengue Virus Infection |
WO2009109550A1 (fr) | 2008-03-05 | 2009-09-11 | Sanofi Pasteur | Procédé de stabilisation d’un adjuvant contenant une composition de vaccin |
EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
SG189048A1 (en) | 2010-10-29 | 2013-05-31 | Merck Sharp & Dohme | Recombinant subunit dengue virus vaccine |
TW201620546A (zh) * | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1159968A1 (fr) | 2000-05-30 | 2001-12-05 | Mahidol University | Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale |
WO2001091790A1 (fr) * | 2000-05-30 | 2001-12-06 | Aventis Pasteur | Composition vaccinale |
US6638514B1 (en) * | 1999-03-26 | 2003-10-28 | The United States Of America As Represented By The Secretary Of The Army | Multivalent dengue virus vaccine |
US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1080370A4 (fr) | 1998-05-29 | 2003-07-30 | Epimmune Inc | Identification d'epitopes dr de restriction largement reactifs |
AU4040400A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
AU3844101A (en) | 2000-02-16 | 2001-08-27 | Us Health | Avirulent, immunogenic flavivirus chimeras |
CN1234852C (zh) * | 2003-01-30 | 2006-01-04 | 上海天甲生物医药有限公司 | 一种以登革热病毒重组复制子为载体的假病毒颗粒疫苗 |
BRPI0408774A (pt) | 2003-03-24 | 2006-03-28 | Scripps Research Inst | vacinas de dna contra crescimento tumoral e seus usos |
KR101536612B1 (ko) * | 2005-06-17 | 2015-07-14 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 1 균주 |
KR101582163B1 (ko) * | 2005-06-17 | 2016-01-05 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 2 균주 |
US20080193477A1 (en) * | 2005-08-10 | 2008-08-14 | Acambis Inc. | Vaccination Against Dengue Virus Infection |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-07-12 FR FR0606324A patent/FR2903605A1/fr not_active Withdrawn
-
2007
- 2007-07-11 CA CA002656349A patent/CA2656349A1/fr not_active Abandoned
- 2007-07-11 AR ARP070103083A patent/AR061887A1/es not_active Application Discontinuation
- 2007-07-11 AU AU2007274100A patent/AU2007274100B2/en not_active Ceased
- 2007-07-11 WO PCT/FR2007/051641 patent/WO2008007021A1/fr active Application Filing
- 2007-07-11 EP EP07823563A patent/EP2043680A1/fr not_active Withdrawn
- 2007-07-11 ZA ZA200900155A patent/ZA200900155B/xx unknown
- 2007-07-11 MY MYPI20085395A patent/MY169275A/en unknown
- 2007-07-11 BR BRPI0712878-9A patent/BRPI0712878A2/pt not_active IP Right Cessation
- 2007-07-11 MX MX2009000369A patent/MX2009000369A/es active IP Right Grant
- 2007-07-11 CN CN2007800263768A patent/CN101489585B/zh not_active Expired - Fee Related
- 2007-07-11 KR KR1020097002307A patent/KR20090027759A/ko not_active Application Discontinuation
- 2007-07-11 JP JP2009518935A patent/JP5295956B2/ja not_active Expired - Fee Related
- 2007-07-12 TW TW096125447A patent/TWI400333B/zh not_active IP Right Cessation
- 2007-07-12 US US11/776,816 patent/US7718357B2/en not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196331A patent/IL196331A0/en unknown
-
2010
- 2010-03-05 US US12/718,091 patent/US20100221285A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638514B1 (en) * | 1999-03-26 | 2003-10-28 | The United States Of America As Represented By The Secretary Of The Army | Multivalent dengue virus vaccine |
EP1159968A1 (fr) | 2000-05-30 | 2001-12-05 | Mahidol University | Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale |
WO2001091790A1 (fr) * | 2000-05-30 | 2001-12-06 | Aventis Pasteur | Composition vaccinale |
US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
Non-Patent Citations (2)
Title |
---|
GUIRAKHOO F ET AL: "Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.", JOURNAL OF VIROLOGY MAY 2004, vol. 78, no. 9, May 2004 (2004-05-01), pages 4761 - 4775, XP002426475, ISSN: 0022-538X * |
HALSTEAD S B ET AL: "Studies on the immunization of monkeys against dengue. I. Protection derived from single and sequential virus infections.", THE AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE MAY 1973, vol. 22, no. 3, May 1973 (1973-05-01), pages 365 - 374, XP009080884, ISSN: 0002-9637 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2526965A1 (fr) * | 2006-10-04 | 2012-11-28 | Sanofi Pasteur | Méthode d'immunisation contre les 4 sérotypes de la Dengue |
EP2099483B1 (fr) * | 2006-12-01 | 2013-12-25 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
US8999675B2 (en) | 2009-08-31 | 2015-04-07 | Gen-Probe Incorporated | Dengue virus assay |
WO2014016360A1 (fr) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Compositions de vaccin |
WO2014016362A1 (fr) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Compositions de vaccin pour prévenir une infection provoquée par le virus de la dengue |
EP3932422A1 (fr) | 2012-07-24 | 2022-01-05 | Sanofi Pasteur | Compositions vaccinales pour la prévention des infections dues au virus de la dengue |
WO2014083194A1 (fr) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Procédés d'induction d'anticorps |
WO2019069130A1 (fr) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | Compositions pour vaccination de rappel contre la dengue |
EP4082568A1 (fr) | 2018-09-05 | 2022-11-02 | Takeda Vaccines, Inc. | Dose unitaire de vaccin contre le virus de la dengue et son administration |
EP3620174A1 (fr) | 2018-09-05 | 2020-03-11 | Takeda Vaccines, Inc. | Dose unitaire de vaccin contre le virus de la dengue et son administration |
WO2020051334A1 (fr) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dose unitaire de vaccin contre la dengue et son administration |
WO2021034349A1 (fr) | 2019-08-16 | 2021-02-25 | Takeda Vaccines, Inc. | Méthode de prévention de la dengue et de l'hépatite a |
WO2021174059A1 (fr) | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Procédé d'élimination d'adn de cellule hôte à partir d'une préparation virale |
WO2023147337A2 (fr) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Production et fabrication de vaccin à flavivirus à grande échelle |
WO2023147342A2 (fr) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Production et fabrication de vaccin flaviviral à grande échelle |
WO2023158989A1 (fr) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Processus d'agitation par lots de vaccin contre la dengue |
WO2023215383A1 (fr) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Détermination par ordinateur d'une infectivité de flavivirus |
WO2024108087A1 (fr) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | Procédé de détermination de la proportion d'un flavivirus vivant atténué ayant une séquence nucléotidique comprenant au moins un locus d'atténuation dans une formulation |
EP4375381A1 (fr) | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | Procédé pour déterminer la proportion d'un flavivirus vivant atténué ayant une séquence nucléotidique comprenant au moins un locus d'atténuation dans une formulation |
WO2024118740A1 (fr) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Production et fabrication de vaccin à flavivirus à grande échelle |
Also Published As
Publication number | Publication date |
---|---|
US7718357B2 (en) | 2010-05-18 |
JP2009542783A (ja) | 2009-12-03 |
TW200813228A (en) | 2008-03-16 |
AU2007274100B2 (en) | 2013-02-07 |
MY169275A (en) | 2019-03-21 |
ZA200900155B (en) | 2010-03-31 |
BRPI0712878A2 (pt) | 2012-09-04 |
MX2009000369A (es) | 2009-01-29 |
AR061887A1 (es) | 2008-10-01 |
EP2043680A1 (fr) | 2009-04-08 |
FR2903605A1 (fr) | 2008-01-18 |
TWI400333B (zh) | 2013-07-01 |
KR20090027759A (ko) | 2009-03-17 |
CN101489585B (zh) | 2013-12-04 |
US20100221285A1 (en) | 2010-09-02 |
CN101489585A (zh) | 2009-07-22 |
IL196331A0 (en) | 2011-08-01 |
JP5295956B2 (ja) | 2013-09-18 |
AU2007274100A1 (en) | 2008-01-17 |
US20080014219A1 (en) | 2008-01-17 |
CA2656349A1 (fr) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2077857B1 (fr) | Methode d'immunisation contre les 4 serotypes de la dengue | |
EP2099483B1 (fr) | Methode d'immunisation contre les 4 serotypes de la dengue | |
WO2008007021A1 (fr) | Methode d'immunisation contre les 4 serotypes de la dengue | |
WO2024086605A1 (fr) | Formulation de vaccin contre la dengue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780026376.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07823563 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2656349 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007274100 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/000369 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 198/CHENP/2009 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009518935 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007823563 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097002307 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2007274100 Country of ref document: AU Date of ref document: 20070711 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0712878 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090112 |